RayKnowChina Research Map
Shortlist

RecruitingPancreatic cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07262567, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Pathologically confirmed pancreatic cancer (derived from pancreatic ductal epithelium) at metastatic stage.

    Inclusion criterion 3

  3. Previous receipt of therapy targeted for KRAS G12D or pan-RAS/KRAS.

    Exclusion criterion 3

    Received radiotherapy within 4 weeks prior to randomization or other local anti-tumor therapy within 4 weeks prior to randomization.

    Exclusion criterion 4

    Received other anti-tumor therapy within 28 days or 5 half-lives (whichever is shorter) prior to randomization.

    Exclusion criterion 5

  4. Participants must have at least one measurable lesion (per RECIST 1.1 criteria).

    Inclusion criterion 5

  5. Other malignant tumors that progressed or required treatment within 3 years prior to randomization.

    Exclusion criterion 1

  6. Pregnant or lactating females.

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07262567, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily participate in the study and sign the informed consent form.
  • Male or female aged 18-80 years (inclusive) at the time of signing the informed consent form.
  • Pathologically confirmed pancreatic cancer (derived from pancreatic ductal epithelium) at metastatic stage.
  • Have received at least one prior standard systemic therapy.
  • Participants must have at least one measurable lesion (per RECIST 1.1 criteria).
  • Expected survival time ≥ 12 weeks as judged by the investigator.
  • Have adequate organ function

Exclusion Criteria:

  • Other malignant tumors that progressed or required treatment within 3 years prior to randomization.
  • With active central nervous system (CNS) metastasis.
  • Previous receipt of therapy targeted for KRAS G12D or pan-RAS/KRAS.
  • Received radiotherapy within 4 weeks prior to randomization or other local anti-tumor therapy within 4 weeks prior to randomization.
  • Received other anti-tumor therapy within 28 days or 5 half-lives (whichever is shorter) prior to randomization.
  • With clinically significant severe cardiovascular diseases.
  • Stroke or other severe cerebrovascular diseases within 6 months prior to randomization.
  • Complicated with major acute or chronic infectious diseases.
  • Have severe mental or psychological diseases, or a history of drug abuse or severe alcoholism.
  • Pregnant or lactating females.
  • Other conditions deemed inappropriate for participation in the study by the investigator.

Quoted from ClinicalTrials.gov, NCT07262567, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07262567, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07262567